Once Daily Dosing of Lonafarnib Co-administered With Ritonavir for Treatment of Chronic Hepatitis D Virus Infection
Status:
Recruiting
Trial end date:
2025-04-30
Target enrollment:
Participant gender:
Summary
Open label, single arm, multi-center clinical trial of lonafarnib 50 mg QD plus ritonavir 200
mg QD, administered orally, over a 48-week treatment period, with a 24-week post-treatment
follow-up period, in patients with chronic Hepatitis D Virusinfection.
Objectives: To evaluate the safety and tolerability of once daily dosing of lonafarnib 50 mg
with ritonavir 200 mg over a 48-week treatment period.
To evaluate the effect of once daily dosing of lonafarnib 50 mg with ritonavir 200 mg over a
48-week treatment period with a 24-week post-treatment follow-up on HDV viral levels.
Trial population: Up to 30 patients with chronic HDV infection with detectable HDV RNA and
compensated liver disease.